not tagged
not tagged
['lymsm', 'cml']
now onto bites in lbcl! makes a case for considerable efficacy of bispecifics in pts with heavily pretreated and primary refractory disease. time-limited glofit with orr 61%, subq but indefinite epcor 68%. #lymsm #17icml 
Lymphoma doc & patient-reported outcomes researcher in #lymsm and #mmsm @CUHematology. Founder of https://t.co/kN6qeGFEox, @inTrainingDoc & @inHouseMag. 🏳️‍🌈